D. W. Denning, K. Riniotis, R. Dobrashian, and H. Sambatakou, Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review, Clin Infect Dis, vol.37, issue.3, pp.265-280, 2003.

N. L. Smith and D. W. Denning, Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma, Eur Respir J, vol.37, pp.865-872, 2011.

A. O. Soubani and P. H. Chandrasekar, The clinical spectrum of pulmonary aspergillosis, Chest, vol.121, pp.1988-1999, 2002.

M. L. Uffredi, G. Mangiapan, J. Cadranel, and G. Kac, Significance of Aspergillus fumigatus isolation from respiratory specimens of nongranulocytopenic patients, Eur J Clin Microbiol Infect Dis, vol.22, pp.457-462, 2003.

J. L. Saraceno, D. T. Phelps, T. J. Ferro, R. Futerfas, and D. B. Schwartz, Chronic necrotizing pulmonary aspergillosis: approach to management, Chest, vol.112, pp.541-548, 1997.

B. Dupont, Itraconazole therapy in aspergillosis: study in 49 patients, J Am Acad Dermatol, vol.23, pp.607-614, 1990.

D. W. Denning, P. Ribaud, N. Milpied, D. Caillot, R. Herbrecht et al., Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis, Clin Infect Dis, vol.34, pp.563-571, 2002.

R. Herbrecht, D. W. Denning, T. F. Patterson, J. E. Bennett, R. E. Greene et al., Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis, N Engl J Med, vol.347, pp.408-415

J. R. Perfect, K. A. Marr, T. J. Walsh, R. N. Greenberg, B. Dupont et al., Voriconazole treatment for lesscommon, emerging, or refractory fungal infections, Clin Infect Dis, vol.36, pp.1122-1131, 2003.

F. Jacobs, D. Selleslag, M. Aoun, A. Sonet, and A. Gadisseur, An observational efficacy and safety analysis of the treatment of acute invasive aspergillosis using voriconazole, Eur J Clin Microbiol Infect Dis, vol.31, pp.1173-1179, 2011.

M. A. Pfaller, S. A. Messer, R. J. Hollis, R. N. Jones, . Sentry-participants et al., Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, Antimicrob Agents Chemother, vol.46, pp.1032-1037, 2000.

R. Herbrecht, Voriconazole: therapeutic review of a new azole antifungal, Expert Rev Anti Infect Ther, vol.2, pp.485-497, 2004.

S. Krishnan, E. K. Manavathu, and P. H. Chandrasekar, A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus, J Antimicrob Chemother, vol.55, pp.914-920, 2005.

B. Capitano, B. A. Potoski, S. Husain, S. Zhang, D. L. Paterson et al., Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen, Antimicrob Agents Chemother, vol.50, pp.1878-1880, 2006.

H. Sambatakou, B. Dupont, H. Lode, and D. W. Denning, Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis, Am J Med, vol.119, pp.527-544, 2006.

L. R. Jain and D. W. Denning, The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis, J Infect, vol.52, pp.133-137, 2006.

J. Camuset, H. Nunes, M. C. Dombret, A. Bergeron, P. Henno et al., Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients, Chest, vol.131, pp.1435-1441, 2007.

, European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2012) Amphotericin B and Aspergillus spp.: rationale for the EUCAST clinical breakpoints, 2012.

P. E. Verweij, S. J. Howard, W. J. Melchers, and D. W. Denning, Azole-resistance in Aspergillus: proposed nomenclature and breakpoints, Drug Resist Updat, vol.12, pp.141-147, 2009.

, Vfend: summary of product characteristics (revision 17), European Medicines Agency, vol.9, 2009.

E. Bart-delabesse, J. F. Humbert, E. Delabesse, and S. Bretagne, Microsatellite markers for typing Aspergillus fumigatus isolates, J Clin Microbiol, vol.36, pp.2413-2418, 1998.
URL : https://hal.archives-ouvertes.fr/hal-02685504

C. Colozza, B. Posteraro, S. Santilli, D. Carolis, E. Sanguinetti et al., In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies, Int J Antimicrob Agents, vol.39, pp.440-443, 2012.

T. J. Walsh, E. J. Anaissie, D. W. Denning, R. Herbrecht, D. P. Kontoyiannis et al., Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America, Infectious Diseases Society of America, vol.46, pp.327-360, 2008.

K. De-beule, D. Doncker, P. Cauwenbergh, G. Koster, M. Legendre et al., The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study (1982-1987), Mycoses, vol.31, pp.476-485, 1988.

T. W. Felton, C. Baxter, C. B. Moore, S. A. Roberts, W. W. Hope et al., Efficacy and safety of posaconazole for chronic pulmonary aspergillosis, Clin Infect Dis, vol.51, pp.1383-1391, 2010.

S. Kohno, K. Izumikawa, K. Ogawa, A. Kurashima, N. Okimoto et al., Japan Chronic Pulmonary Aspergillosis Study Group (JCPASG) et al (2010) Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan, J Infect, vol.61, pp.410-418

K. Izumikawa, Y. Ohtsu, M. Kawabata, H. Takaya, A. Miyamoto et al., Clinical efficacy of micafungin for chronic pulmonary aspergillosis, Med Mycol, vol.45, pp.273-278, 2007.

S. Kohno, T. Masaoka, H. Yamaguchi, T. Mori, A. Urabe et al., A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan, Scand J Infect Dis, vol.36, pp.372-379, 2004.

A. Pascual, T. Calandra, S. Bolay, T. Buclin, J. Bille et al., Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes, Clin Infect Dis, vol.46, pp.201-211, 2008.